Piloting home infusions of Tysabri (natalizumab): a randomised crossover trial

19th International Conference on Integrated Care, San Sebastian, 01-03 April 2019

Tim Schultz, Anne Thomas, Paul Georgiou, Mahasen Juaton, Lorraine Simon, Lynette Cusack, Kerisha Naidoo, Kevin Webb, Jon Karnon

University of Adelaide, Australia

We developed a new model of care for home infusions of natalizumab for people with multiple sclerosis. The new model of care was then tested in a pilot study comparing home infusions of natalizumab with usual care (attendance in an ambulatory care day units) using an AB/BA randomised crossover trial. In addition to testing feasibility and safety of home infusions for people with natalizumab compared to usual care, we investigated if: (i) home infusions of natalizumab are acceptable to patients and healthcare staff, (ii) home infusions of natalizumab are as effective in treating symptoms, and (iii) home infusions of natalizumab are cost effective?

There were 37 stable adult patients (at least 6 prior natalizumab infusions and assessed as safe by their neurologist) randomised to an AB or BA trial arm. After 3 infusions, patients crossed over to the alternate treatment for another 3 infusions.

Keywords: patient centred care; home infusion; natalizumab; multiple sclerosis